EPISODE · Mar 24, 2023 · 4 MIN
FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer
from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Listen to a soundcast of the March 3, 2023, FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer.
NOW PLAYING
FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer
No transcript for this episode yet
Similar Episodes
Apr 26, 2026 ·35m
Apr 25, 2026 ·141m
Apr 24, 2026 ·55m
Apr 23, 2026 ·54m
Apr 22, 2026 ·40m
Apr 21, 2026 ·64m